REATA PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of debt issuance costs and imputed interest
Non-cash interest expense on liability related to sale of future royalty
Stock-based compensation expense
Amortization of discount (premium) on marketable debt securities
Loss on extinguishment of debt
Gain on lease termination
Changes in operating assets and liabilities:
Income tax receivable and payable
Prepaid expenses, other current assets and other assets
Other assets
Accounts payable
Accrued direct research, other current and long-term liabilities
Operating lease obligations
Payable to collaborators
Deferred revenue

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Purchases of marketable securities
Maturity from marketable securities
Net cash used in investing activities
Financing activities
Proceeds from issuance of common stock, net
Payments on deferred offering costs
Payments on long-term debt
Payments on deferred issuance costs
Proceeds from payments of shareholder promissory notes
Exercise of options
Proceeds from sale of future royalties, net
Net cash provided by financing activities

Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of period
Supplemental disclosures
Cash paid for interest
Non-cash activity:
Accrued deferred offering cost
Right-of-use assets obtained in exchange for lease obligations
Purchases of equipment in accounts payable, accrued direct research, other current, and long-term liabilities
Acquisition of property and equipment through tenant improvement allowance current, and long-term liabilities

Comments